At #ESMO26, #BioNTech shares 16 abstracts across 10 tumor types. Highlights: late-breaking oral presentation of first data from ROSETTA Lung-107 for an investigational PD-L1×VEGF bispecific+chemotherapy in 2L mNSCLC, and novel IO+ADC combination data. 🔗 bit.ly/4juFXJE

Read more 🔗: bit.ly/4hXzqpm

🎗 Not every breast cancer journey looks the same. For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time. Here are 5 reasons why continued research matters, during #BreastCancerAwarenessMonth and every day.

Lung cancer is not one disease. Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain. Watch 👇 #LungCancer #CancerResearch

📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer. 🔗 Learn more: bit.ly/4h5DjqL #LungCancer #WCLC26

We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer. 🔗 Learn more: bit.ly/4gaKY7W #LungCancer #Oncology #WCLC26 #BioNTech

Photo copyright Guido Oelkers: Sobi - Swedish Orphan Biovitrum AB (publ), 2026

📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: bit.ly/4h9thXn

We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more. Explore the many: bit.ly/3TuyK13 #WorldLungCancerDay

At #ASCO26, we presented interim data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating an investigational PD-L1 x VEGF-A bispecific immunomodulator in 1L squamous and non-squamous #NSCLC.

The candidate is being developed by BioNTech and OncoC4. Join the proffered paper session at 3:35 pm CET in Auditorium A1.

Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.

Join the poster session at 1:00 pm CET in the Foyer.

Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews